- Policy
- Lily's orphan drug 'Jaypirca' receives conditional approval
- by Lee, Hye-Kyung Aug 30, 2024 05:50am
- 'Jaypirca,' a designated orphan drug for the treatment of Mantle Cell Lymphoma that recently received marketing authorization in South Korea, is expected to submit the Phase 3 trial results showing therapeutic confirmation by March 2027. As it received conditional approval based on Phase ½ clinical trial results, the company must compare
- Policy
- Reimb standards set for biliary tract cancer drug Pemazyre
- by Lee, Tak-Sun Aug 30, 2024 05:50am
- Pemazyre (pemigatinib), a targeted therapy for biliary tract cancer supplied to Korea by Handok, has successfully received reimbursement standards from the Health Insurance Review and Assessment Service's Cancer Disease Review Committee (CDDC). The reimbursement standards for the immuno-oncology drug Tevimbra were also set at the meeting. Mer
- Policy
- Prices of Dukarb, Rosuzet cut 3 yrs through PVA
- by Lee, Tak-Sun Aug 30, 2024 05:49am
- The insurance ceiling price of 6 drugs has been cut for 3 consecutive years through the price-volume agreement ‘Type C’ negotiations. According to the industry on the 28th, 6 drugs, including Boryung Pharmaceutical’s 'Dukarb', Dong-A ST 'Growtropin II Inj’, Hanmi Pharmaceutical’s 'Rosuzet Tab', Janssen Korea’s 'Concerta Oros ER Tab’
- Policy
- Will RWD-based reimb agreements be more beneficial?
- by Lee, Tak-Sun Aug 29, 2024 04:31am
- Drug reimbursement contracts satisfy all parties involved when they achieve three goals: The first is patient access, the second is sustained revenue for the pharmaceutical company, and the third is budget management for the payer. “A fair price is one that can satisfy both the seller and the buyer,” said So-young Lee, Director of Hea
- Policy
- Price of 17 items cut 30% during Type C PVA negotiations
- by Lee, Tak-Sun Aug 28, 2024 05:52am
- The National Health Insurance Service (NHIS) has announced that it has achieved health insurance financial savings of KRW 52.1 billion (USD 52.1 million) through ‘Type C’ Price-Volume Agreement (PVA) negotiations this year. This is an 85.5% increase from the KRW 28.1 billion in the previous year. In particular, the revision of the deta
- Policy
- MFDS to review side effects relief imposed on companies
- by Lee, Jeong-Hwan Aug 28, 2024 05:52am
- The Ministry of Food and Drug Safety (MFDS) announced that it would try to set the reasonably sized 'Payment for Benefits for relief of Injury from Side Effects of Drugs, (hereafter referred to as payment for benefits for relief) ' which is currently charged to pharmaceutical companies. MFDS' audit of the Korea Institute of Drug Safety
- Policy
- SK Chemicals strengthens migraine drug lineup with Suvexx
- by Lee, Tak-Sun Aug 27, 2024 05:50am
- Suvexx, a combination migraine treatment imported and supplied by SK Chemicals, will be reimbursed in Korea next month. Suvexx is a combination of sumatriptan, a triptan-class drug most commonly used for migraine, and naproxen, a non-steroidal anti-inflammatory drug (NSAID). According to industry sources on the 26th, Suvexx will be lis
- Policy
- Eliquis generics re-enter the market, 35 reimbursed drugs
- by Lee, Tak-Sun Aug 26, 2024 05:46am
- Drugs that are generic versions of the coagulant agent Eliquis (apixaban) will re-enter the market three and five months after discontinuing sales due to a failing patent nullification challenge. It is because the original drug's substance patent is set to expire on September 9th. According to sources on August 23rd, generics containi
- Policy
- Hanmi faces competition from cheaper Zytiga generic drug
- by Lee, Tak-Sun Aug 26, 2024 05:45am
- A new competing drug has entered the 'Zytiga' generic market, where Hanmi Pharmaceutical was the only company to launch a product last year. Ace Pharmaceutical has introduced a drug imported from India to the South Korean market. While Hanmi Pharmaceutical is strengthening its market presence by recently launching a combination drug
- Policy
- DREC to review the COVID-19 drug Paxlovid a week earlier
- by Lee, Tak-Sun Aug 23, 2024 06:17am
- The Drug Reimbursement Evaluation Committee (DREC) of the Health Insurance Review and Assessment Service (HIRA) will convene a week earlier than scheduled. The DREC review evaluates the appropriateness of new drugs for reimbursement. Industry analysis suggests that the schedule has changed to quickly list the COVID-19 treatment 'Paxlovid
